Avet announces launch of Doxycycline Hyclate Delayed Release Tablets
Avet Pharmaceuticals Inc. announced the immediate availability of Doxycycline Hyclate delayed release tablets in 75, 100, and 150 mg strengths. This product is the AB rated generic equivalent to the antibiotic drug Doryx® and adds to Avet’s robust portfolio of high barrier, extended release oral solid products. According to IMS data for the twelve-months ended May 2013, the U.S. market for Doxycycline Hyclate approximated $160 million.